Avacta Group Share News (AVCT)
AVCT Share
AVCT Share
AVCT Share
AVCT Share
AVCT
AVCT Share
AVCT Level 2
AVCT Live
AVCT Broker
AVCT Directors
AVCT Financial
AVCT
AVCT Short
AVCT
Last checked at -
Thu, 23rd Aug 2018 17:38
LONDON (Alliance News) - Avacta Group PLC said Thursday that FIL Ltd decreased its stake in the biotechnology company to below 5% after a transaction on Tuesday.
FIL lowered its holding to less than 5% of shares. Prior to the transaction, FIL held a 6.1% stake in the company.
Shares in Avacta closed up 2.9% at 25.00 pence per share on Thursday.
(Sharecast News) - Cancer therapies and diagnostics company Avacta announced on Monday that its 'AffiDX' SARS-CoV-2 rapid antigen lateral flow test detected the dominant new variants of coronavirus, known as the B117 or 'Kent', variant, and the D614G variant, as well as the original strain.
Read moreTRADING UPDATES: Avacta Plans Covid Test Launch Near First Quarter End
Read moreAIM WINNERS & LOSERS: Mkango Hails Pilot Plant Processing Milestone
Read moreAIM WINNERS & LOSERS: Clear Leisure Surges Amid Placing, Bitcoin Plans
Read moreAvacta Focusing On Full Clinical Validation Of Rapid Covid-19 Test
Read more(Sharecast News) - Avacta Group responded to some press speculation on take-up of its lateral flow SARS-CoV-2 rapid antigen test for Covid-19 by the UK government on Monday.
Read moreLONDON MARKET OPEN: European Equities Slip Amid Inflation Fears
Read moreIN BRIEF: Avacta Gets Phase I Clinical Trial Approval For AVA6000
Read more(Sharecast News) - Biotherapeutics and reagents developer Avacta has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) for a phase 1 study of its lead 'preCISION' pro-drug, AVA6000 pro-doxorubicin, it announced on Thursday.
Read moreAIM WINNERS & LOSERS: Cornish Metals Jumps 40% On AIM Debut
Read moreAvacta Shares Surge On Positive Data For Covid-19 Antigen Test
Read more(Sharecast News) - Biotherapeutics and reagents developer Avacta Group has received the first data for its SARS-CoV-2 rapid antigen test from ongoing clinical studies in Europe and the UK, it announced on Tuesday.
Read more(Sharecast News) - Biotherapeutics developer Avacta Group has entered into a commercial partnership with Mologic, it announced on Monday, to accelerate to market its 'AffiDX' SARS-CoV-2 lateral flow rapid antigen test.
Read moreAIM WINNERS & LOSERS: Bahamas Petroleum Sinks As Pulls Plug On Well
Read moreAvacta Signs Agreement With Mologic For AffiDX Covid-19 Antigen Test
Read more
Last checked at